drugset / Trial / NCT05932277
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and fexofenadine (P-gp substrate), in healthy participants.
Timeline
- Start
- 2023-06-29
- Primary completion
- 2023-09-13
- Completion
- 2023-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986419 | Unknown | — | — |
| Subject | Bupropion | Small molecule | — | — |
| Subject | Caffeine | Small molecule | — | — |
| Subject | Fexofenadine | Unknown | — | — |
| Subject | Flurbiprofen | Small molecule | — | — |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Omeprazole | Other / unclassified | — | — |
Indications
No indication recorded.